Drugs / Pediarix
Pediarix
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00505063 | Jul 2007 → Jun 2025 | childhood malignant neoplasm | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00133445 | Dec 2005 → Aug 2006 | diphtheria, hepatitis B virus infection, pertussis, poliomyelitis +1 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01000974 | Jun 2010 → Nov 2011 | haemophilus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00879827 | Sep 2000 → May 2001 | diphtheria, hepatitis B virus infection, poliomyelitis, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 2 | NCT00129129 Background | Aug 2004 → Sep 2005 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT07160244 Background | Aug 2025 → Nov 2028 expected | — | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT03621670 Background | Jul 2018 → Dec 2024 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT03207750 Background | Sep 2017 → Oct 2018 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02096263 Comparator | Apr 2014 → Feb 2015 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, poliomyelitis +1 | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01978093 Background | Feb 2014 → Mar 2016 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00614614 Background | Feb 2008 → Jul 2009 | meningococcal infection | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT00289783 Background | Feb 2006 → Aug 2007 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pediarix | “With the recent licensure in the US of a pentavalent combination vaccine (DTaP-Hep B-IPV; Pediarix™) researchers propose to evaluate a new immunization schedule that includes a...” NCT00133445 ↗ |
| Known as | DTaP-HepB-IPV | “DTaP-HepB-IPV (Pediarix™) vaccine” NCT00133445 ↗ |
| Known as | DTPa-HBV-IPV | “Pediarix (DTPa-HBV-IPV) was administered intramuscularly on Day 1, Day 61, and Day 121.” NCT03621670 ↗ |
| Known as | Infanrix penta | “Pediarix TM, Infanrix penta TM” NCT00879827 ↗ |
| Modality | Vaccine | “Pediarix™ and Prevnar™ vaccines” NCT00129129 ↗ |
| Route | Intramuscular | “Pediarix™ and Prevnar™ vaccines IM in the left upper and lower thighs, respectively” NCT00129129 ↗ |